Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

NCT01465464 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01465464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01465464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2010
Completion date
November 30, 2014
Enrollment
888 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma